De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study

Canagliflozin is a sodium-glucose co-transporter 2 inhibitor that reduces glycemia as well as the risk of cardiovascular events. Our main objective was to analyze antidiabetic treatment de-intensification and the glycemic efficacy of replacing antidiabetic agents (excluding metformin) with canaglifl...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Belmonte, Luis M., Ricci, Michele, Sanz-Cánovas, Jaime, Cobos-Palacios, Lidia, López-Carmona, María D., Ruiz-Moreno, M. Isabel, Millán-Gómez, Mercedes, Bernal-López, M. Rosa, Jansen-Chaparro, Sergio, Gómez-Huelgas, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125841/
https://www.ncbi.nlm.nih.gov/pubmed/34066707
http://dx.doi.org/10.3390/jcm10092013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125841/
https://www.ncbi.nlm.nih.gov/pubmed/34066707
http://dx.doi.org/10.3390/jcm10092013

Ejemplares similares